Entropic Biosciences is developing a new approach to 3D tissue engineering designed to make human-relevant models faster, more reproducible, and easier to scale for drug discovery and safety testing. Its ZYRALIX™ biomaterial technology enables cells to self-assemble into multicellular organoids and tissues in less than 24 hours, offering an alternative to conventional hydrogel- and scaffold-based culture methods.
The company’s first commercial application is a 3D human skin organoid platform built for screening-friendly workflows. The model is designed to support studies of skin barrier formation and maturation, injury and recovery, chemical and radiation exposure, and dermatological drug responses while helping researchers bridge the gap between simplified 2D cultures and more variable or difficult-to-scale ex vivo tissue models.
Entropic’s broader platform is being developed for high-throughput drug screening, toxicology, infectious disease research, precision medicine, and other New Approach Methodology applications. By combining rapid tissue formation with scalable workflows, the company aims to make advanced human tissue models more practical for routine preclinical research and ultimately improve the efficiency and relevance of therapeutic development.
